By Karen Roman ReAlta Life Sciences, Inc. said it was granted Orphan Drug Designation by the European Medicines Agency (EMA) for RLS-0071 (pegtarazimod), to treat Graft-versus-Host Disease (GvHD). The designation was supported by preliminary data from the company’s Phase 2 trial...

CorpGov is pleased to announce the final agenda for the inaugural LA CorpGov Forum on Thursday, September 4, 2025, at 1500 N El Centro Ave, Los Angeles, California, in the heart of Hollywood. The forum will start at 2:00pm featuring...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG) said it received FDA and EMA clearance for GLORA-4, a global registrational Phase III trial of their Bcl-2 inhibitor lisaftoclax for first-line treatment of higher-risk myelodysplastic syndrome. The company said it is addressing...

Download the Complete Report Here By Rayk Riechmann With the final major citrus harvest finished in its third fiscal quarter, Alico, Inc. (Nasdaq: ALCO) completed a major strategic shift towards transforming into a diversified land management company. Finalizing this key...

Subscribe to our Weekly Newsletter to Receive All Research Contact: Executives-Edge.com Rayk@capmarketsmedia.com

Download the Complete Report Here By Rayk Riechmann Binah Capital Group, Inc. (Nasdaq: BCG) reported an in-line quarter of top-line growth, driven by a surge in its assets under management (AUM). BCG’s revenue grew by 2%, backed by increased profitability...

Contact: Executives-Edge.com Rayk@capmarketsmedia.com

By Daniella Parra Recent IPO AIRO Group Holdings, Inc. (Nasdaq: AIRO) posted its first results as a public company, with second quarter revenue surging 151% to $24.6 million and adjusted EBITDA reaching $4.7 million, up 710%. Gross margin expanded to...

Download the Complete Report Here By Rayk Riechmann Another impressive top-line beat by Aurora Cannabis Inc. (Nasdaq: ACB) should have investors fired up. The company reported a 17% revenue increase in its first fiscal quarter, mostly driven by a strong...